Modest synergy was seen when G47ΔV-mIL-12 was combined with single agent ICPI (PD-1 or CTLA-4), however triple therapy (OV/PD-1/CTLA-4) led to long-term cures and protection from tumour re-challenge. This evidence concerns the gene PDCD1 and neoplasm.